IN2012DN03177A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03177A IN2012DN03177A IN3177DEN2012A IN2012DN03177A IN 2012DN03177 A IN2012DN03177 A IN 2012DN03177A IN 3177DEN2012 A IN3177DEN2012 A IN 3177DEN2012A IN 2012DN03177 A IN2012DN03177 A IN 2012DN03177A
- Authority
- IN
- India
- Prior art keywords
- targeting molecule
- conjugated
- complex
- antibody
- moiety
- Prior art date
Links
- 230000008685 targeting Effects 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or I9F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, ' F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26677309P | 2009-12-04 | 2009-12-04 | |
US30228010P | 2010-02-08 | 2010-02-08 | |
US31612510P | 2010-03-22 | 2010-03-22 | |
US34748610P | 2010-05-24 | 2010-05-24 | |
US38172010P | 2010-09-10 | 2010-09-10 | |
US38826810P | 2010-09-30 | 2010-09-30 | |
PCT/US2010/058724 WO2011068965A1 (en) | 2009-12-04 | 2010-12-02 | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03177A true IN2012DN03177A (en) | 2015-09-25 |
Family
ID=44115287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3177DEN2012 IN2012DN03177A (en) | 2009-12-04 | 2010-12-02 |
Country Status (8)
Country | Link |
---|---|
US (3) | US8202509B2 (en) |
EP (1) | EP2507254A4 (en) |
JP (1) | JP5789821B2 (en) |
CN (1) | CN102666567B (en) |
AU (1) | AU2010326004B2 (en) |
CA (1) | CA2782223A1 (en) |
IN (1) | IN2012DN03177A (en) |
WO (1) | WO2011068965A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US20100226884A1 (en) * | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US8545809B2 (en) * | 2007-01-11 | 2013-10-01 | Immunomedics, Inc. | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules |
US8709382B2 (en) * | 2007-01-11 | 2014-04-29 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US8889100B2 (en) * | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US20160045626A1 (en) * | 2007-01-11 | 2016-02-18 | Immunomedics, Inc. | Methods and Compositions for Improved Labeling of Targeting Peptides |
US8398956B2 (en) * | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
US10556873B2 (en) | 2008-02-22 | 2020-02-11 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
WO2010011367A2 (en) * | 2008-02-22 | 2010-01-28 | Illinois Institute Of Technology | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using |
US10189803B2 (en) | 2008-02-22 | 2019-01-29 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
WO2012082618A2 (en) * | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
WO2011068965A1 (en) * | 2009-12-04 | 2011-06-09 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
CA2838198A1 (en) * | 2011-06-09 | 2012-12-13 | Ge Healthcare Limited | Distillation device and method |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
GB201201062D0 (en) | 2012-01-23 | 2012-03-07 | Ge Healthcare Ltd | Radiofluorination method |
EP2854845B1 (en) | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
CN102675329B (en) * | 2012-06-05 | 2014-12-24 | 浙江大学 | Positron emission tomography agent and preparation method thereof |
US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
CN102911256B (en) * | 2012-11-02 | 2016-06-01 | 厦门大学 | Polypeptides complexe of a kind of radio-labeling and its preparation method and application |
KR102069104B1 (en) * | 2012-11-30 | 2020-01-22 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Polypeptide and imaging method |
WO2014164553A1 (en) | 2013-03-13 | 2014-10-09 | Imaginab, Inc. | Antigen binding constructs to cd8 |
CN103267850B (en) * | 2013-04-27 | 2015-04-15 | 深圳先进技术研究院 | Probe for pathological diagnosis of tumor, and preparation method and application thereof |
GB201308053D0 (en) * | 2013-05-03 | 2013-06-12 | Ge Healthcare Ltd | Metal complexes and fluorination thereof |
WO2015051362A1 (en) | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
EP3077407A4 (en) * | 2013-12-03 | 2017-07-19 | Millennium Pharmaceuticals, Inc. | Compounds and compositions for imaging gcc-expressing cells |
WO2015119763A1 (en) * | 2014-02-06 | 2015-08-13 | Immunomedics, Inc. | Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer |
US20160331852A1 (en) * | 2015-05-11 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Radioligands for pretargeted pet imaging and methods of their therapeutic use |
CA2984630A1 (en) * | 2015-07-07 | 2017-01-12 | Immunomedics, Inc. | Improved methods of imaging with ga-68 labeled molecules |
CN115960230A (en) | 2015-08-07 | 2023-04-14 | 伊麦吉纳博公司 | Antigen binding constructs for targeting molecules |
US9623118B2 (en) * | 2015-09-01 | 2017-04-18 | Immunwork Inc. | Multi-arm linker constructs for treating pathological blood clots |
WO2017070752A1 (en) * | 2015-10-29 | 2017-05-04 | The University Of Queensland | Imaging agents |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
CN107312070A (en) * | 2017-05-03 | 2017-11-03 | 厦门大学附属第医院 | It is a kind of18PET polypeptide probes of F marks and preparation method thereof |
CN108314678B (en) * | 2018-01-17 | 2019-11-08 | 浙江大学 | Using phosphatidylserine as molecular probe of target spot and application thereof |
EP3774803A1 (en) | 2018-03-30 | 2021-02-17 | Centre national de la recherche scientifique | Pyclen-based macrocyclic ligands, chelates thereof and uses thereof |
JP2022501312A (en) * | 2018-07-26 | 2022-01-06 | タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド | Compositions and methods for imaging |
KR20210113201A (en) * | 2019-01-07 | 2021-09-15 | 아스텔라스세이야쿠 가부시키가이샤 | Complex comprising a ligand and a CEACAM5 antibody Fab fragment |
AU2020332618A1 (en) * | 2019-08-21 | 2022-02-24 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive metal complex |
CN112285361B (en) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | Agent for eliminating interference of anti-CD 38 monoclonal antibody medicine against human globulin detection |
JPWO2022211051A1 (en) * | 2021-03-31 | 2022-10-06 | ||
CN113773365A (en) * | 2021-09-09 | 2021-12-10 | 原子高科股份有限公司 | Somatostatin analogs and uses thereof |
EP4273142A1 (en) | 2022-05-06 | 2023-11-08 | Université de Bretagne Occidentale | Picolinate cyclam palladium chelates and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2604092B1 (en) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
US5446147A (en) * | 1992-04-03 | 1995-08-29 | Trustees Of The University Of Pennsylvania | Fluorinated and iodinated dopamine agents |
WO1999011590A1 (en) * | 1997-09-03 | 1999-03-11 | Immunomedics, Inc. | Fluorination of proteins and peptides for f-18 positron emission tomography |
US6071490A (en) * | 1998-05-07 | 2000-06-06 | Immunomedics, Inc. | Position emission tomography using gallium-68 chelates |
US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US7387772B1 (en) * | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US6056939A (en) * | 1998-08-28 | 2000-05-02 | Desreux; Jean F. | Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals |
DE19846148C2 (en) * | 1998-10-01 | 2002-10-10 | Igor Popov | Method for assessing the oxidative modification of proteinaceous substances by measuring their antiradical activity |
US6207858B1 (en) * | 1999-03-03 | 2001-03-27 | Idec Pharmaceuticals Corporation | Regioselective synthesis of DTPA derivatives |
MXPA02003772A (en) * | 1999-10-15 | 2005-04-28 | Mayo Foundation | Cobalamin conjugates useful as imaging and therapeutic agents. |
US6605615B2 (en) * | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
EP2052742A1 (en) * | 2000-06-20 | 2009-04-29 | Biogen Idec Inc. | Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination |
US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
US7081452B2 (en) * | 2002-06-03 | 2006-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same |
US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US7993626B2 (en) * | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
ATE517638T1 (en) * | 2003-01-31 | 2011-08-15 | Immunomedics Inc | METHOD AND PREPARATIONS FOR ADMINISTERING THERAPEUTIC AND DIAGNOSTIC AGENTS |
CA2533878A1 (en) * | 2003-07-29 | 2005-09-22 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
EP2581382A2 (en) * | 2004-02-13 | 2013-04-17 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
DE102004034517A1 (en) * | 2004-07-16 | 2006-02-16 | Covion Organic Semiconductors Gmbh | metal complexes |
US20060029544A1 (en) * | 2004-08-06 | 2006-02-09 | The Regents Of The University Of California Office Of Technology Transfer | Receptor-binding cyclic peptides and methods of use |
EP1874824A4 (en) * | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
AU2006285278B2 (en) * | 2005-08-31 | 2011-05-12 | Immunomedics, Inc. | F-18 peptides for pre targeted positron emission tomography imaging |
TWI303332B (en) * | 2006-08-04 | 2008-11-21 | Largan Precision Co Ltd | Optical lens assembly |
CA2663454C (en) * | 2006-09-15 | 2015-04-21 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US8398956B2 (en) * | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
EP2117604B1 (en) * | 2007-01-11 | 2017-07-26 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
WO2011068965A1 (en) * | 2009-12-04 | 2011-06-09 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
-
2010
- 2010-12-02 WO PCT/US2010/058724 patent/WO2011068965A1/en active Application Filing
- 2010-12-02 CN CN201080052555.0A patent/CN102666567B/en active Active
- 2010-12-02 CA CA2782223A patent/CA2782223A1/en not_active Abandoned
- 2010-12-02 US US12/958,889 patent/US8202509B2/en active Active
- 2010-12-02 JP JP2012542186A patent/JP5789821B2/en active Active
- 2010-12-02 IN IN3177DEN2012 patent/IN2012DN03177A/en unknown
- 2010-12-02 EP EP10835120.6A patent/EP2507254A4/en not_active Withdrawn
- 2010-12-02 AU AU2010326004A patent/AU2010326004B2/en active Active
-
2012
- 2012-05-17 US US13/474,260 patent/US8444956B2/en active Active
-
2013
- 2013-03-26 US US13/850,591 patent/US8617518B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8202509B2 (en) | 2012-06-19 |
CN102666567B (en) | 2015-08-26 |
JP2013512918A (en) | 2013-04-18 |
US20120282178A1 (en) | 2012-11-08 |
AU2010326004B2 (en) | 2016-04-21 |
US20130211044A1 (en) | 2013-08-15 |
EP2507254A1 (en) | 2012-10-10 |
US8444956B2 (en) | 2013-05-21 |
WO2011068965A1 (en) | 2011-06-09 |
CN102666567A (en) | 2012-09-12 |
CA2782223A1 (en) | 2011-06-09 |
EP2507254A4 (en) | 2013-12-04 |
JP5789821B2 (en) | 2015-10-07 |
US20110110854A1 (en) | 2011-05-12 |
US8617518B2 (en) | 2013-12-31 |
AU2010326004A1 (en) | 2012-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03177A (en) | ||
WO2012082618A3 (en) | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules | |
EP2291678A4 (en) | Improved methods and compositions for f-18 labeling of proteins, peptides and other molecules | |
MX2010005022A (en) | Antibodies that bind human dendritic and epithelial cell 205 (dec-205). | |
GEP20196956B (en) | Anti-gcc antibody molecules and related compositions and methods | |
MX340674B (en) | Zirconium-radiolabeled, cysteine engineered antibody conjugates. | |
MX2010005830A (en) | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use. | |
MX355181B (en) | Human antibodies against human tissue factor. | |
EP2117604A4 (en) | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules | |
WO2011039510A3 (en) | Conjugates targeting the cd163 receptor | |
MX357193B (en) | Anti-alpha synuclein binding molecules. | |
UA115402C2 (en) | CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3 | |
HK1162119A1 (en) | Animal models and therapeutic molecules | |
NZ712035A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
MX2012011768A (en) | Antibodies that bind human cd27 and uses thereof. | |
GB0718957D0 (en) | Optical imaging agents | |
TN2009000063A1 (en) | Compounds and methods for 18f labeled agents | |
NZ610239A (en) | Cross-linkers and their uses | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
NZ593964A (en) | Human anti-alpha-synuclein autoantibodies | |
MX2010000537A (en) | Monoclonal antibodies against glypican-3. | |
EP2792236A3 (en) | Animal models and therapeutic molecules | |
MX2009010412A (en) | Compositions for targeted imaging and therapy. | |
NZ587701A (en) | Anti-trka antibodies and derivatives thereof | |
IN2012DN04908A (en) |